Turning Tumors into Vaccines: Co-opting the Innate Immune System

Immunity

Volumn 39, Issue 1, 2013, Pages 27-37

  Van den Boorn, Jasper G ^a   Hartmann, Gunther ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLAMMASOME; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; IPILIMUMAB; LAMBOLIZUMAB; PACLITAXEL; SMALL INTERFERING RNA; TASQUINIMOD; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VEMURAFENIB;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC INFLAMMATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; INNATE IMMUNITY; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; UNSPECIFIED SIDE EFFECT;

APOPTOSIS; CANCER VACCINES; CYTOKINES; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84880719582     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2013.07.011     Document Type: Review

References (107)

1. Agarwal P., Raghavan A., Nandiwada S.L., Curtsinger J.M., Bohjanen P.R., Mueller D.L., Mescher M.F. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8 Tcell effector function and memory. J.Immunol. 2009, 183:1695-1704.
2. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., Huhn R.D., Song W., Li D., Sharp L.L., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
3. Besch R., Poeck H., Hohenauer T., Senft D., Häcker G., Berking C., Hornung V., Endres S., Ruzicka T., Rothenfusser S., Hartmann G. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J.Clin. Invest. 2009, 119:2399-2411.
4. Bijker M.S., van den Eeden S.J.F., Franken K.L., Melief C.J.M., van der Burg S.H., Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 2008, 38:1033-1042.
5. Bos R., Sherman L.A. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010, 70:8368-8377.
6. Brahmer J.R., Tykodi S.S., Chow L.Q.M., Hwu W.-J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N.Engl. J. Med. 2012, 366:2455-2465.
7. Bruchard M., Mignot G., Derangère V., Chalmin F., Chevriaux A., Végran F., Boireau W., Simon B., Ryffel B., Connat J.L., et al. Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth. Nat. Med. 2013, 19:57-64.
8. Bunt S.K., Sinha P., Clements V.K., Leips J., Ostrand-Rosenberg S. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J.Immunol. 2006, 176:284-290.
9. Cerullo V., Diaconu I., Romano V., Hirvinen M., Ugolini M., Escutenaire S., Holm S.-L., Kipar A., Kanerva A., Hemminki A. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance. Mol. Ther. 2012, 20:2076-2086.
10. Chen D.S., Mellman I. Oncology Meets Immunology: The Cancer-Immunity Cycle. Immunity 2013, 39:1-10. this issue.
11. Coley W.B. II. Contribution to the Knowledge of Sarcoma. Ann. Surg. 1891, 14:199-220.
12. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.-I., Cheng P., Cho H.-I., Celis E., Quiceno D.G., Padhya T., et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J.Exp. Med. 2010, 207:2439-2453.
13. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., Thompson R., Schioppa T., Nemeth J., Vermeulen J., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin. Cancer Res. 2011, 17:6083-6096.
14. Curtsinger J.M., Schmidt C.S., Mondino A., Lins D.C., Kedl R.M., Jenkins M.K., Mescher M.F. Inflammatory cytokines provide a third signal for activation of naive CD4+ and CD8+ Tcells. J.Immunol. 1999, 162:3256-3262.
15. De Santo C., Salio M., Masri S.H., Lee L.Y.-H., Dong T., Speak A.O., Porubsky S., Booth S., Veerapen N., Besra G.S., et al. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloid-derived suppressor cells in mice and humans. J.Clin. Invest. 2008, 118:4036-4048.
16. Demaria S., Formenti S.C. Radiation as an immunological adjuvant: current evidence on dose and fractionation. Front Oncol 2012, 2:153.
17. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 2002, 3:991-998.
18. DuPage M., Mazumdar C., Schmidt L.M., Cheung A.F., Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012, 482:405-409.
19. Ellermeier J., Wei J., Duewell P., Hoves S., Stieg M.R., Adunka T., Noerenberg D., Anders H.-J., Mayr D., Poeck H., et al. Therapeutic efficacy of bifunctional siRNA combining TGF-β1 silencing with RIG-I activation in pancreatic cancer. Cancer Res. 2013, 73:1709-1720.
20. Fehleisen, F. (1883). Die Etiologie des Erysipels (Berlin).
21. Fife B.T., Pauken K.E., Eagar T.N., Obu T., Wu J., Tang Q., Azuma M., Krummel M.F., Bluestone J.A. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat. Immunol. 2009, 10:1185-1192.
22. Flaherty K.T., Puzanov I., Kim K.B., Ribas A., McArthur G.A., Sosman J.A., O'Dwyer P.J., Lee R.J., Grippo J.F., Nolop K., Chapman P.B. Inhibition of mutated, activated BRAF in metastatic melanoma. N.Engl. J. Med. 2010, 363:809-819.
23. Forsbach A., Müller C., Montino C., Kritzler A., Nguyen T., Weeratna R., Jurk M., Vollmer J. Negative regulation of the type I interferon signaling pathway by synthetic Toll-like receptor 7 ligands. J. Interferon Cytokine Res. 2012, 32:254-268.
24. Fortin C., Huang X., Yang Y. NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. J.Immunol. 2012, 189:1843-1849.
25. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., Fitz L.J., Malenkovich N., Okazaki T., Byrne M.C., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J.Exp. Med. 2000, 192:1027-1034.
26. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
27. Gajewski T.F. Cancer immunotherapy. Mol. Oncol. 2012, 6:242-250.
28. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A., Tarpey P., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N.Engl. J. Med. 2012, 366:883-892.
29. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., Sawyers C.L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
30. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
31. Greten F.R., Eckmann L., Greten T.F., Park J.M., Li Z.-W., Egan L.J., Kagnoff M.F., Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004, 118:285-296.
32. Guarda G., Braun M., Staehli F., Tardivel A., Mattmann C., Förster I., Farlik M., Decker T., Du Pasquier R.A., Romero P., et al. Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34:213-223.
33. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.-J., Kefford R., Wolchok J.D., Hersey P., Joseph R.W., Weber J.S., et al. Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. N.Engl. J. Med. 2013.
34. Heit A., Schmitz F., O'Keeffe M., Staib C., Busch D.H., Wagner H., Huster K.M. Protective CD8 Tcell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines. J.Immunol. 2005, 174:4373-4380.
35. Hernandez-Alcoceba R., Berraondo P. Immunochemotherapy against colon cancer by gene transfer of interleukin-12 in combination with oxaliplatin. OncoImmunology 2012, 1:97-99.
36. Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J.Transl. Med. 2011, 9:216.
37. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N.Engl. J. Med. 2010, 363:711-723.
38. Hornung V., Ellegast J., Kim S., Brzózka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.-K., Schlee M., et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
39. Iborra S., Izquierdo H.M., Martínez-López M., Blanco-Menéndez N., Reis e Sousa C., Sancho D. The DC receptor DNGR-1 mediates cross-priming of CTLs during vaccinia virus infection in mice. J.Clin. Invest. 2012, 122:1628-1643.
40. Iyori M., Zhang T., Pantel H., Gagne B.A., Sentman C.L. TRAIL/DR5 plays a critical role in NK cell-mediated negative regulation of dendritic cell cross-priming of Tcells. J.Immunol. 2011, 187:3087-3095.
41. Joffre O.P., Sancho D., Zelenay S., Keller A.M., Reis e Sousa C. Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. Eur. J. Immunol. 2010, 40:1255-1265.
42. Kanneganti T.D., Body-Malapel M., Amer A., Park J.H., Whitfield J., Franchi L., Taraporewala Z.F., Miller D., Patton J.T., Inohara N., Núñez G. Critical role for Cryopyrin/Nalp3 in activation of caspase-1 in response to viral infection and double-stranded RNA. J.Biol. Chem. 2006, 281:36560-36568.
43. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., Redfern C.H., Ferrari A.C., Dreicer R., Sims R.B., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N.Engl. J. Med. 2010, 363:411-422. IMPACT Study Investigators.
44. Karin M., Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 2005, 5:749-759.
45. Kenter G.G., Welters M.J.P., Valentijn A.R.P.M., Lowik M.J.G., Berends-van der Meer D.M.A., Vloon A.P.G., Essahsah F., Fathers L.M., Offringa R., Drijfhout J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N.Engl. J. Med. 2009, 361:1838-1847.
46. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., Leonardi A.J., Morgan R.A., Wang E., Marincola F.M., et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J.Clin. Invest. 2011, 121:4746-4757.
47. Khan S., Bijker M.S., Weterings J.J., Tanke H.J., Adema G.J., van Hall T., Drijfhout J.W., Melief C.J.M., Overkleeft H.S., van der Marel G.A., et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J.Biol. Chem. 2007, 282:21145-21159.
48. Kohlmeyer J., Cron M., Landsberg J., Bald T., Renn M., Mikus S., Bondong S., Wikasari D., Gaffal E., Hartmann G., Tüting T. Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy. Cancer Res. 2009, 69:6265-6274.
49. Landsberg J., Gaffal E., Cron M., Kohlmeyer J., Renn M., Tüting T. Autochthonous primary and metastatic melanomas in Hgf-Cdk4 R24C mice evade T-cell-mediated immune surveillance. Pigment Cell Melanoma Res 2010, 23:649-660.
50. Landsberg J., Kohlmeyer J., Renn M., Bald T., Rogava M., Cron M., Fatho M., Lennerz V., Wölfel T., Hölzel M., Tüting T. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation. Nature 2012, 490:412-416.
51. Lattanzi L., Rozera C., Marescotti D., D'Agostino G., Santodonato L., Cellini S., Belardelli F., Gavioli R., Ferrantini M. IFN-α boosts epitope cross-presentation by dendritic cells via modulation of proteasome activity. Immunobiology 2011, 216:537-547.
52. Leach D.R., Krummel M.F., Allison J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996, 271:1734-1736.
53. Leffers N., Lambeck A.J.A., Gooden M.J.M., Hoogeboom B.-N., Wolf R., Hamming I.E., Hepkema B.G., Willemse P.H.B., Molmans B.H.W., Hollema H., et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phaseII trial. Int. J. Cancer 2009, 125:2104-2113.
54. Leffers N., Vermeij R., Hoogeboom B.-N., Schulze U.R., Wolf R., Hamming I.E., van der Zee A.G., Melief K.J., van der Burg S.H., Daemen T., Nijman H.W. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int. J. Cancer 2012, 130:105-112.
55. Lindau D., Gielen P., Kroesen M., Wesseling P., Adema G.J. Theimmunosuppressive tumour network: myeloid-derived suppressor cells, regulatory Tcells and natural killer Tcells. Immunology 2013, 138:105-115.
56. Luzhna L., Golubov A., Ilnytskyy S., Chekhun V.F., Kovalchuk O. Molecular mechanisms of radiation resistance in doxorubicin-resistant breast adenocarcinoma cells. Int. J. Oncol. 2013, 42:1692-1708.
57. Lynch T.J., Bondarenko I., Luft A., Serwatowski P., Barlesi F., Chacko R., Sebastian M., Neal J., Lu H., Cuillerot J.M., Reck M. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J.Clin. Oncol. 2012, 30:2046-2054.
58. Madar S., Goldstein I., Rotter V. 'Cancer associated fibroblasts' - more than meets the eye. Trends Mol. Med. 2013.
59. Matsushita H., Vesely M.D., Koboldt D.C., Rickert C.G., Uppaluri R., Magrini V.J., Arthur C.D., White J.M., Chen Y.-S., Shea L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482:400-404.
60. Merlo L.M.F., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat. Rev. Cancer 2006, 6:924-935.
61. Meyer C., Sevko A., Ramacher M., Bazhin A.V., Falk C.S., Osen W., Borrello I., Kato M., Schadendorf D., Baniyash M., Umansky V. Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model. Proc. Natl. Acad. Sci. USA 2011, 108:17111-17116.
62. Mocellin S., Mandruzzato S., Bronte V., Lise M., Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol. 2004, 5:681-689.
63. Motz G.T., Coukos G. Deciphering and Reversing Tumor ImmuneSuppression. Immunity 2013, 39:61-73. this issue.
64. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
65. Nazarian R., Shi H., Wang Q., Kong X., Koya R.C., Lee H., Chen Z., Lee M.-K., Attar N., Sazegar H., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
66. Nishimura H., Nose M., Hiai H., Minato N., Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
67. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
68. Orsini F., Pavelic Z., Mihich E. Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res. 1977, 37:1719-1726.
69. Palucka K., Banchereau J. Dendritic-Cell-Based Therapeutic Cancer Vaccines. Immunity 2013, 39:38-48. this issue.
70. Pichlmair A., Schulz O., Tan C.P., Näslund T.I., Liljeström P., Weber F., Reis e Sousa C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. Science 2006, 314:997-1001.
71. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
72. Pili R., Häggman M., Stadler W.M., Gingrich J.R., Assikis V.J., Björk A., Nordle O., Forsberg G., Carducci M.A., Armstrong A.J. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer. J.Clin. Oncol. 2011, 29:4022-4028.
73. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S.S., Kirschnek S., Gaffal E., Landsberg J., Hellmuth J., et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat. Med. 2008, 14:1256-1263.
74. Poeck H., Bscheider M., Gross O., Finger K., Roth S., Rebsamen M., Hannesschläger N., Schlee M., Rothenfusser S., Barchet W., et al. Recognition of RNA virus by RIG-I results in activation of CARD9 and inflammasome signaling for interleukin 1 β production. Nat. Immunol. 2010, 11:63-69.
75. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., Mu Z., Rasalan T., Adamow M., Ritter E., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N.Engl. J. Med. 2012, 366:925-931.
76. Quakkelaar E.D., Melief C.J. Experience with synthetic vaccines for cancer and persistent virus infections in nonhuman primates and patients. Adv. Immunol. 2012, 114:77-106.
77. Rajan J.V., Warren S.E., Miao E.A., Aderem A. Activation of the NLRP3 inflammasome by intracellular poly I:C. FEBS Lett. 2010, 584:4627-4632.
78. Raué H.-P., Brien J.D., Hammarlund E., Slifka M.K. Activation of virus-specific CD8+ Tcells by lipopolysaccharide-induced IL-12 and IL-18. J.Immunol. 2004, 173:6873-6881.
79. Raué H.-P., Beadling C., Haun J., Slifka M.K. Cytokine-mediated programmed proliferation of virus-specific CD8(+) memory Tcells. Immunity 2013, 38:131-139.
80. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E.K., Camphausen K., Luiten R.M., de Ru A.H., Neijssen J., et al. Radiation modulates the peptide repertoire, enhances MHC classI expression, and induces successful antitumor immunotherapy. J.Exp. Med. 2006, 203:1259-1271.
81. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the Tcell response. Nat. Rev. Immunol. 2012, 12:269-281.
82. Robert C., Thomas L., Bondarenko I., O'Day S., M D J.W., Garbe C., Lebbe C., Baurain J.-F., Testori A., Grob J.-J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N.Engl. J. Med. 2011, 364:2517-2526.
83. Sancho D., Joffre O.P., Keller A.M., Rogers N.C., Martínez D., Hernanz-Falcón P., Rosewell I., Reis e Sousa C. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 2009, 458:899-903.
84. Scarlett U.K., Cubillos-Ruiz J.R., Nesbeth Y.C., Martinez D.G., Engle X., Gewirtz A.T., Ahonen C.L., Conejo-Garcia J.R. In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. Cancer Res. 2009, 69:7329-7337.
85. Schlee M., Roth A., Hornung V., Hagmann C.A., Wimmenauer V., Barchet W., Coch C., Janke M., Mihailovic A., Wardle G., et al. Recognition of5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity 2009, 31:25-34.
86. Schurich A., Pallett L.J., Lubowiecki M., Singh H.D., Gill U.S., Kennedy P.T., Nastouli E., Tanwar S., Rosenberg W., Maini M.K. The third signal cytokine IL-12 rescues the anti-viral function of exhausted HBV-specific CD8 Tcells. PLoS Pathog. 2013, 9:e1003208.
87. Schuurhuis D.H., Ioan-Facsinay A., Nagelkerken B., van Schip J.J., Sedlik C., Melief C.J.M., Verbeek J.S., Ossendorp F. Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses invivo. J.Immunol. 2002, 168:2240-2246.
88. Schwitalla S., Fingerle A.A., Cammareri P., Nebelsiek T., Göktuna S.I., Ziegler P.K., Canli O., Heijmans J., Huels D.J., Moreaux G., et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. Cell 2013, 152:25-38.
89. Semmling V., Lukacs-Kornek V., Thaiss C.A., Quast T., Hochheiser K., Panzer U., Rossjohn J., Perlmutter P., Cao J., Godfrey D.I., et al. Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat. Immunol. 2010, 11:313-320.
90. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., Schreiber R.D. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
91. Shirota Y., Shirota H., Klinman D.M. Intratumoral injection of CpGoligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J.Immunol. 2012, 188:1592-1599.
92. Steding C.E., Wu S.T., Zhang Y., Jeng M.H., Elzey B.D., Kao C. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 2011, 133:221-238.
93. Sumida K., Wakita D., Narita Y., Masuko K., Terada S., Watanabe K., Satoh T., Kitamura H., Nishimura T. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur. J. Immunol. 2012, 42:2060-2072.
94. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N.Engl. J. Med. 2012, 366:2443-2454.
95. van Montfoort N., Camps M.G., Khan S., Filippov D.V., Weterings J.J., Griffith J.M., Geuze H.J., van Hall T., Verbeek J.S., Melief C.J., Ossendorp F. Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc. Natl. Acad. Sci. USA 2009, 106:6730-6735.
96. Vermeij R., Leffers N., Hoogeboom B.-N., Hamming I.L.E., Wolf R., Reyners A.K.L., Molmans B.H.W., Hollema H., Bart J., Drijfhout J.W., et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study. Int. J. Cancer 2012, 131:E670-E680.
97. Wang T.L., Diaz L.A., Romans K., Bardelli A., Saha S., Galizia G., Choti M., Donehower R., Parmigiani G., Shih IeM., et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc. Natl. Acad. Sci. USA 2004, 101:3089-3094.
98. Wang Y., Ludwig J., Schuberth C., Goldeck M., Schlee M., Li H., Juranek S., Sheng G., Micura R., Tuschl T., et al. Structural and functional insights into 5'-ppp RNA pattern recognition by the innate immune receptor RIG-I. Nat. Struct. Mol. Biol. 2010, 17:781-787.
99. Wong S.B.J., Bos R., Sherman L.A. Tumor-specific CD4+ Tcells render the tumor environment permissive for infiltration by low-avidity CD8+ Tcells. J.Immunol. 2008, 180:3122-3131.
100. Xiao Z., Casey K.A., Jameson S.C., Curtsinger J.M., Mescher M.F. Programming for CD8 Tcell memory development requires IL-12 or type I IFN. J.Immunol. 2009, 182:2786-2794.
101. Yang J.C., Hughes M., Kammula U., Royal R., Sherry R.M., Topalian S.L., Suri K.B., Levy C., Allen T., Mavroukakis S., et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J.Immunother. 2007, 30:825-830.
102. Zeestraten E.C.M., Speetjens F.M., Welters M.J.P., Saadatmand S., Stynenbosch L.F.M., Jongen R., Kapiteijn E., Gelderblom H., Nijman H.W., Valentijn A.R.P.M., et al. Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial. Int. J. Cancer 2013, 132:1581-1591.
103. Zelenay S., Keller A.M., Whitney P.G., Schraml B.U., Deddouche S., Rogers N.C., Schulz O., Sancho D., Reis e Sousa C. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J.Clin. Invest. 2012, 122:1615-1627.
104. Zheng Y., Xu M., Li X., Jia J., Fan K., Lai G. Cimetidine suppresses lung tumor growth in mice through proapoptosis of myeloid-derived suppressor cells. Mol. Immunol. 2013, 54:74-83.
105. Zitvogel L., Apetoh L., Ghiringhelli F., Kroemer G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 2008, 8:59-73.
106. Zoglmeier C., Bauer H., Nörenberg D., Wedekind G., Bittner P., Sandholzer N., Rapp M., Anz D., Endres S., Bourquin C. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 2011, 17:1765-1775.
107. Zom G.G.P., Khan S., Filippov D.V., Ossendorp F. TLR ligand-peptide conjugate vaccines: toward clinical application. Adv. Immunol. 2012, 114:177-201.